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our series. Still, 11.5% of patients have
no mutation after extensive analysis of
the OCA1–4, OCA6, OA1, and HPS1
genes, thus suggesting that other genes
involved in OCA still remain to be
identified.
Written informed consent was
received from the patients. The authors
adhere to the Declaration of Helsinki
Principles. Experiments were approved
by the Comite´ de protection des Per-
sonnes Bordeaux—Outre Mer III.
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TO THE EDITOR
Revertant mosaicism is the coexistence
of mutant cells carrying germline
mutations and revertant cells that have
spontaneously corrected the germline
mutation by a somatic reverse mutation.
Revertant mosaicism has been reported
for a number of genetic diseases
(Pasmooij and Jonkman, 2012), includ-
ing epidermolysis bullosa. Moreover,
the first case of revertant mosaicism in
skin was found in a Dutch patient
026-01 with junctional epidermolysis
bullosa caused by mutations in
COL17A1. The patient was compound
heterozygous for a maternal deletion in
exon 18, c.1601delA, and paternal
nonsense mutation in exon 51,
c.3676C4T (Jonkman et al, 1997).
Owing to gene conversion, the
c.1601delA mutation was corrected
and the patient presented a clinically
healthy skin patch on her forearm
(Figure 1a), where affected (mutant)
and corrected (revertant) keratinocytes
coexisted (Figure 1b). Recently, we
found revertant mosaicism to occur in
all Dutch patients with junctional epi-
dermolysis bullosa (Jonkman and
Pasmooij, 2009; Pasmooij et al, 2012).
Naturally corrected keratinocytes
expressing type XVII collagen (C17)
harvested from a revertant patch can
be used for autologous cell therapy.Accepted article preview online 24 July 2013; published online 15 August 2013
Abbreviation: C17, type XVII collagen
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Unfortunately, the first attempt to trans-
plant revertant keratinocytes did not
succeed because of a surprisingly low
percentage of revertant cells in the graft
(3%) (Gostynski et al, 2009). To explain
the depletion of revertant cells, we have
analyzed the process of skin equivalent
production. Additionally, we have
decided to study the feasibility of rever-
tant cell therapy in an animal model to
assess the long-term survival of revertant
cells after engraftment.
Written, informed consent was
obtained, and all procedures were con-
ducted in accordance with the Declara-
tion of Helsinki principles. Our revertant
cell source was the revertant patch
on the forearm of patient 026-01
(Figure 1a). A previous biopsy specimen
from this area stained for C17 showed
50% revertant cells (Figure 1b; Jonkman
et al, 1997; Pasmooij et al, 2005, 2012).
Next to the earlier diagnostic biopsy
location, a 6-mm punch biopsy was
taken (Figure 1c), from which keratino-
cytes and fibroblasts were isolated
with collagenase and trypsine/EDTA
enzymatic digestion and cultured as
described before (Llames et al, 2006).
Keratinocytes were cultured on a feeder
layer and passaged when confluent to
expand the culture for animal model
experiments and banking. The first
passage was performed 9 days after
isolation and the second passage (p2)
was done 7 days later. During both
passages a side sample was taken,
cultured on coverslips, airfixed, and
the number of revertant cells was asses-
sed by immunofluorescence (IF) micro-
scopy with the 1A8C mAb against C17
(gift from Dr K. Owaribe, Nagoya,
Japan). Stainings showed 40% revertant
cells after first passage, and 25%
revertant cells after the second passage
(Figure 1e and i). A sample of the
keratinocytes was further cultured,
which led to a drop of revertant cells
to 15%, 1%, and o1% after passage 3,
4, and 5, respectively. Growth potential
was tested using colony-forming
efficiency assay, which showed that
cells isolated from the revertant patch
had growth potential comparable to
keratinocytes from a healthy patient
(Supplementary 1 online). Colonies
were further stained with VK4 mAb,
which revealed that the colony-
forming potential was higher in
revertant cells (39% of colonies were
revertant compared with 15% of rever-
tant cells in the population used for the
assay), but their division rate, repre-
sented by colony size, was lower
(Figure 1d).
From the cultured patient’s fibroblasts
and p2 keratinocytes, a 75-cm2 bioen-
gineered skin equivalent was produced
as described before (Llames et al, 2004,
2006). Briefly, a plasma-based scaffold
filled with fibroblasts was used as a
dermal component of the bioenginee-
red revertant skin: 7.5104 cultured
fibroblasts were resuspended in 10 ml
of donor plasma (obtained from the
blood bank), 10 mg of tranexamic acid
(Amchafibrin, Rotapharm, Barcelona,
Spain), and 2 ml of CaCl2 1%, and
adjusted to 25 ml by adding NaCl
0.9%. The mixture was placed in a
75-cm2 tissue culture flask and allowed
to solidify at 37 1C for 30 minutes. Once
the dermal equivalent solidified, it was
covered with culture medium and
24 h later cultured keratinocytes were
seeded. After 8 days, when keratino-
cytes reached confluence, the skin
equivalent was harvested and moved
to the animal facility. The equivalent
was then divided into four pieces, 9 cm2
each, for grafting, and samples were
frozen for the C17 immunofluore-
scence analysis. The sample sections
were stained with 1A8C mAb against
C17 and analyzed by the measurement
of C17-positive fragments. This analysis
revealed that 20% of the graft consisted
of revertant cells (Figure 1f).
Four immunodeficient nu/nu mice
were transplanted as described before
(Llames et al 2004; Garcia et al, 2007).
Biopsies from the engrafted skin
(Figure 1g) were taken after 10 and 16
weeks and directly frozen in liquid
nitrogen. Each of the four biopsies was
cut into 4-mm sections and stained
with 1A8C or VK4 mAb (Dr HH Pas,
Groningen, The Netherlands) (Yuen,
2012) against C17 to assess revertant
cell survival, and with mAb (AF109)
specific for murine keratin 1 (Prof
D Roop, Denver, Colorado, USA)
(Yuspa et al, 1989) to distinguish
human and murine epidermis. Once
again, the length of C17-positive frag-
ments and the total length were measu-
red and analysis revealed that revertant
cells were present in 20% area of the
human epidermis after both time points
(Figure 1h and i). This corresponded
with the percentage of revertant
cells found in the skin equivalent and
suggested a long-term survival of C17-
producing cells. To prove that the rever-
sion mechanism was present in the
areas positive for C17, laser dissection
microscopy followed by nested PCR
was performed on all biopsies as
described earlier (Pasmooij et al,
2005). In fragments of human epider-
mis positive for C17, we found the
same post-zygotic reversion mutation
as in donor site keratinocytes on the
patient’s forearm, i.e. the loss by gene
conversion of the maternal COL17A1:
c.1601delA mutation.
The reason for a decreased percen-
tage of revertant cells remains unknown.
It has been shown that C17 influences
hair follicle stem cells in mice and that
cells lacking C17 have a different phe-
notype in vitro (Hamill et al, 2011).
Furthermore, C17 deficiency activates
a proinflammatory pathway by upregu-
lation of NF-kB, whereas in healthy
keratinocytes that express C17, levels
of NF-kB are low (Van den Bergh et al,
2012). Therefore, the growth advantage
in cultures of C17-negative keratino-
cytes over C17-positive keratinocytes
might be explained by NF-kB activa-
tion that stimulates epidermal prolife-
ration in the C17-negative cells
(Duheron et al, 2011). Further studies
are required to assess whether such
differences account for a growth
advantage of mutant keratinocytes. To
overcome the in vitro depletion of
revertant cells for a therapeutic
approach, a method for selection of
C17 revertant cells compatible with
clinical patient care is needed.
In this study we show that, after a
marked decrease during in vitro expan-
sion on plastic, the percentage of rever-
tant keratinocytes stabilizes during skin
equivalent production and remains
stable in vivo (Figure 1i). This proves
the long-term survival of revertant kera-
tinocytes, suggesting that we trans-
planted revertant epidermal stem cells.
Hereby, we demonstrate the feasibility
of the revertant cell therapy for C17-
deficient patients.
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Figure 1. Long-term survival of C17 revertant cells in a skin-humanized mouse model. (a) Patient 026-01: left arm, outlined revertant patches with black asterisks.
The red asterisk marks the location of the previous diagnostic biopsy specimen. (b) Immunofluorescence of the diagnostic biopsy showing 50% of the cells being
revertant (white asterisks). (c) Biopsy for cell culture is taken from the revertant patch (outlined) next to the previous diagnostic biopsy location (red asterisk).
(d) Immunohistochemical staining of the colony-forming efficiency assay with VK4 mAb showing two small revertant colonies (red asterisks) next to a large mutant
colony (black asterisk). (e) Cultured keratinocytes on coverslips stained with 1A8C mAb (green) against the intracellular domain of C17. In blue cell nuclei.
Revertant keratinocytes are marked with white asterisks. (f) Samples of skin equivalent stained with 1A8C mAb (green). White asterisks indicate the revertant
regions of the epidermis. (g) Revertant graft (white asterisk) on mouse back 6 weeks after transplantation. Pigmentation is visible where human skin is present.
(h) Graft on mouse sampled 10 weeks after transplantation and stained with VK4 mAb (green) against the intracellular domain of C17 and with mAb against mouse
keratin 1 (red). In blue cell nuclei. The white line separates murine (Mouse) and human (Human) epidermis. (i) Percentage of revertant cells during in vitro culture,
production of the skin equivalent, and after transplantation. For in vitro analysis after passage 1 and 2, 4,761 and 2,924 cells were counted, respectively.
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TO THE EDITOR
Se´zary syndrome (SS), mycosis fun-
goides (MF), and transformed mycosis
fungoides (TMF; Olsen et al., 2007)
belong to the heterogeneous group of
cutaneous T-cell lymphoma (CTCL).
They are characterized as extranodal
non-Hodgkin lymphoma from malig-
nant, mature T lymphocytes that home
to the skin and persist there (Girardi
et al., 2004). SS and MF are the most
common CTCL types. Recent genetic
and phenotypic studies suggest that MF
and SS, previously considered as diffe-
rent stages of the same disease, arise
from two distinct T-cell subsets (van
Doorn et al., 2009; Campbell et al.,
2010). Pathological diagnosis is often
hampered by the small proportion of
malignant cells and by the morphologi-
cal similarity to inflammatory skin
diseases (ISDs). Thus, a reliable cuta-
neous biomarker able to distinguish
malignant cells from reactive benign
T cells in the infiltrate of CTCL is still
needed. Most previous studies have
focused on blood malignant T lympho-
cytes in patients with leukemic disease
(Vonderheid et al., 2001; Ferenczi et al.,
2002; Su et al., 2003; Bensussan et al.,
2011). When skin samples were consi-
dered, a specific expression of EphA4,
Twist, TOX, PDCD1, or CDK158k/
KIR3DL2 gene was found in MF or SS
patients.
NKp46 has been shown on blood
malignant CD4þ T lymphocytes in SS
but not in MF or in TMF (Bensussan
et al., 2011). NKp46 belongs to naturalAccepted article preview online 30 July 2013; published online 29 August 2013
Abbreviations: CBCL, cutaneous B-cell lymphoma; CTCL, cutaneous T-cell lymphoma; ISD, inflammatory
skin disease; LM, laser microdissection; NCR, natural cytotoxicity receptor; RT-PCR, real-time PCR; SEM,
standard error of the mean; SS, Se´zary syndrome; MF, mycosis fungoides; TMF, transformed mycosis
fungoides
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